Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.04, $0.06 better than the analyst estimate of $1.98. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.2 billion.

GUIDANCE:

Quest Diagnostics sees Q2 2023 EPS of $8.45-$8.95, versus the consensus of $8.71. Quest Diagnostics sees Q2 2023 revenue of $8.93-9.08 billion, versus the consensus of $8.98 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.